Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022

Rhea-AI Summary

Passage Bio (NASDAQ: PASG) will host a conference call on November 10, 2022, at 8:30 a.m. ET to discuss its third quarter 2022 financial results and recent business updates. The company focuses on genetic therapies for CNS disorders and is advancing three clinical programs targeting GM1 gangliosidosis, Krabbe disease, and frontotemporal dementia. Passage Bio collaborates with the University of Pennsylvania’s Gene Therapy Program for its research and development efforts. Archived webcasts will be available post-event for 30 days.

Positive

• Collaborative agreement with the University of Pennsylvania enhances R&D capabilities.
• Advancing three clinical programs targeting CNS disorders.

Negative

• None.

PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, November 10, 2022, to report its third quarter 2022 financial results and discuss recent business updates.

To access the live conference call and webcast, please register here. The archived webcast will be available on Passage Bio's website approximately two hours after the completion of the event and for 30 days following the call.

About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical-stage genetic medicines company on a mission to provide life-transforming therapies for patients with CNS diseases with limited or no approved treatment options. Our portfolio spans pediatric and adult CNS indications, and we are currently advancing three clinical programs in GM1 gangliosidosis, Krabbe disease and frontotemporal dementia with several additional programs in preclinical development. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. Through this collaboration, we have enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.

For further information, please contact:

Passage Bio Investors:
Stuart Henderson
Passage Bio
267-866-0114
shenderson@passagebio.com

Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312-961-2502
MikeBeyer@sambrown.com 

FAQ

What is the date and time for Passage Bio's third quarter earnings call?

Passage Bio's third quarter earnings call is scheduled for November 10, 2022, at 8:30 a.m. ET.

What conditions are Passage Bio's clinical programs targeting?

Passage Bio is targeting GM1 gangliosidosis, Krabbe disease, and frontotemporal dementia in its clinical programs.

Where can I access the webcast for Passage Bio's earnings call?

The webcast for the earnings call can be accessed through the company's website and will be available for 30 days after the call.